Kronos Bio Shares Fall After Initial-Stage Blood Cancer Study Takes-off

Kronos Bio KRON has initiated patient dosing in a Phase 1b/2 clinical trial of lanraplenib in combination with gilteritinib in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia (AML).
The Phase 1b/2 lanraplenib clinical trial is a multi-center dose-escalation study enrolling patients with relapsed/refractory FLT3-mutated AML.

The first stage of the study will evaluate initial safety, pharmacokinetic and anti-leukemic activity of escalating once-daily doses of lanraplenib in combination with the standard approved dose of gilteritinib.

After the recommended dose is established, an expansion stage is planned to further evaluate the safety of lanraplenib.

Jorge DiMartino, Chief medical officer and Executive vice president, stated, "The initiation of this study is an important first step as we advance lanraplenib for patients with certain genetically defined types of AML. Our long-term vision is to develop lanraplenib as a cornerstone of targeted regimens for these patients, allowing us to potentially reach as many as two-thirds of patients with AML.”

Acute myeloid leukemia (AML) primarily affects adults and is one of the most difficult-to-treat blood cancers.

Price Action : Kronos shares are trading around 5 percent down at $4.06 on Monday at the time of publication.